SCHEMBL22492123

SCHEMBL22492123

O=C(O)[C@@H]1CCC(F)(F)C[C@H]1c1ccco1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.38
KDM4E B2RXH2 4/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
TSHR P16473 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
ALOX5 P09917 2/20 0.38
KCNQ3 O43525 2/20 0.38
KCNQ2 O43526 2/20 0.38
KCNQ4 P56696 1/20 0.38
KCNQ5 Q9NR82 1/20 0.38
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22492125 1.00 POLB (0.38) POLBKDM4EKMT2AALDH1A1MEN1
SCHEMBL22492122 1.00 POLB (0.38) POLBKDM4EKMT2AALDH1A1MEN1
SCHEMBL23646316 0.79 BRD4 (0.38) ALDH1A1TSHRALOX5CHRM2CHRM4
SCHEMBL23646317 0.79 BRD4 (0.38) ALDH1A1TSHRALOX5CHRM2CHRM4
SCHEMBL23646313 0.79 BRD4 (0.38) ALDH1A1TSHRALOX5CHRM2CHRM4
SCHEMBL22492104 0.78 KCNQ3 (0.53) POLBALDH1A1TSHRKCNQ3KCNQ2
SCHEMBL22492105 0.78 KCNQ3 (0.53) POLBALDH1A1TSHRKCNQ3KCNQ2
SCHEMBL22492099 0.78 KCNQ3 (0.53) POLBALDH1A1TSHRKCNQ3KCNQ2
SCHEMBL22492087 0.77 POLB (0.40) POLBTSHRKCNQ3KCNQ2KCNQ4
SCHEMBL22492086 0.77 POLB (0.40) POLBTSHRKCNQ3KCNQ2KCNQ4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332472-B2 Substituted piperidines as inhibitors of ubiquitin specific protease 7 LES LABORATOIRES SERVIER (FR) 2022-05-17 US disclosed
US-20200407363-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 LES LABORATOIRES SERVIER (FR) 2020-12-31 US disclosed
EP-3717482-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Les Laboratoires Servier SAS (FR) 2020-10-07 EP disclosed
CN-111542524-A Novel piperidinyl derivatives as inhibitors of ubiquitin-specific protease 7 法国施维雅药厂 2020-08-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332472-B2 Substituted piperidines as inhibitors of ubiquitin specific protease 7 USP7, PSMA7, PSMB7 POLB 1500/4885KDM4E 878/4885KMT2A 815/4885
US-20200407363-A1 NEW PIPERIDINYL DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 PSMB7, PSMA7, USP7 POLB 1423/4885KDM4E 1069/4885KMT2A 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.